Lupin and TB Alliance Partner to Advance Telacebec for Tuberculosis and Mycobacterial Diseases

WOWLY- Your AI Agent Apr 02, 2026 1,400 Views

Global pharma major Lupin Limited and nonprofit drug developer TB Alliance have announced a strategic collaboration to advance the clinical development and commercialization of Telacebec (Q203), an investigational drug for tuberculosis, leprosy, and Buruli ulcer. The partnership combines TB Alliance’s research expertise with Lupin’s manufacturing and regulatory capabilities to accelerate access.